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Abstract 
 
The purpose of this study was to develop a quantitative structure-activity relationship 
(QSAR) for the prediction of the apparent volume of distribution (Vd) in humans for a 
heterogeneous series of drugs. The relationship of many computed, and some 
experimental, structural descriptors with Vd, and the Vd corrected for protein binding 
(unbound Vd), was investigated. Models were constructed using stepwise regression 
analysis for all the 70 drugs in the dataset, as well as for acidic drugs and basic drugs 
separately. The predictive power of the models was assessed using half the chemicals as 
a test set, and revealed that the models for Vd yielded lower prediction errors than those 
constructed for the unbound Vd (mean fold error of 2.01 for Vd compared to 2.28 for 
unbound Vd). Moreover, the separation of the compounds into acids and bases did not 
reduce the prediction error significantly. 
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Introduction 
Modern drug design focuses not only on the pharmacological activity of a compound 
but also considers a range of other properties including its pharmacokinetic behaviour. 
A successful drug candidate should demonstrate, amongst others, the ability to be 
absorbed, to reach its site of action and a suitable half-life. In recent years there has 
been an enormous interest in the prediction of human pharmacokinetic properties using 
different methods ranging from computational approaches to using in vitro and in vivo 
data. This is due to the fact that a large proportion of drugs fail in development due to 
poor absorption, distribution, metabolism and elimination (ADME) properties (Kennedy 
1997). The aim of these studies is to provide screening tools for drugs at a very early 
stage of development. Animal pharmacokinetic studies are a routine tool to predict drug 
behaviour in man. Furthermore, human-derived cellular or subcellular systems have 
been developed to measure permeation, membrane transport, absorption, distribution, 
metabolism and excretion; the systems as summarised by Balant and Gex-Fabry (2001) 
include partition coefficients, caco-2 cell monolayers, plasma protein binding, 
microsomes, hepatocytes and enzyme systems. QSAR methods provide models not only 
for prediction of pharmacological activity but also for toxicological endpoints, 
membrane-passage and pharmacokinetics parameters. Prediction of oral absorption has 
been a hot research topic in recent years, with Lipinski’s rule of five (Lipinski et al 
1997) at an early stage leading to the application of both linear and non-linear QSAR 
methods to the prediction of oral absorption (for more recent works see Raevsky et al 
2002; Palm et al 1997; Ghafourian & Barzegar-Jalali 2002; Van de Waterbeemd 2002; 
Klopman et al 2002; Zhao et al 2002). A detailed review of the methods to predict 
pharmacokinetic properties has been published by Egan and Lauri (2002). Other routes 
of absorption including skin (Ghafourian & Fooladi 2000; Moss et al 2002), as well as 
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permeability through cell lines (Kulkarni et al 2002; Tantishaiyakul 2001), artificial 
membranes (Kansy et al 2001; Agatonovic-Kustrin et al 2001) and the blood-brain 
barrier (Abraham et al 1999) have also been explored.  
Volume of distribution, clearance and elimination half-life are three of the most 
important pharmacokinetic properties. Various quantitative structure-pharmacokinetic 
relationships (QSPRs) have been developed for several congeneric series of molecules 
and different mathematical models have been proposed (Gobburu & Shelver 1995; 
Turner et al 2003; Van der Graaf et al 1999). Models have been proposed for non-
aromatics, aromatics and heteroaromatics to allocate the chemicals into three ratings of 
volume of distribution (Hirono et al 1994) and neural network (Ritschel et al 1995) and 
multivariate (Karalis et al 2002) methods have been employed to model volume of 
distribution. This study has focused on the distribution process of drugs. The volume of 
distribution of the central compartment (VC) is used to correlate plasma concentration of 
a drug at time zero (C0) to the amount of drug in the body (X) (Shargel & Yu 1999) by 
the expression: 
X = VC * C0 (1) 
Two different terms have been used to describe the volume of distribution for drugs that 
follow multiple exponential decay. The first, designated Varea, is calculated as the ratio 
of clearance to the rate of decline of concentration during the elimination (final) phase 
of the logarithmic concentration versus time curve: 
Varea = dose/k.AUC (2) 
The second volume term is the volume of distribution at steady state (Vss) which 
represents the volume in which a drug would appear to be distributed during steady 
state if the drug existed throughout that volume at the same concentration as that in the 
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measured fluid (plasma or blood). When using pharmacokinetics to make drug dosing 
decisions, the differences between Varea and Vss are not usually clinically significant 
(Wilkinson 2001). In this investigation QSAR methods have been employed in order to 
predict the apparent volume of distribution of drugs in humans. The compounds used in 
this study were drug entities with unrelated chemical structures. Predictions have been 
made based on different QSAR models for acidic drugs and basic drugs separately, as 
well as for all the drugs together. The Vd parameter was used either untransformed or 
corrected for plasma protein binding. A comparison with previous QSAR, and other 
prediction methods, is made. 
 
Materials and Methods  
 
Pharmacokinetic Data 
Data for the volume of distribution at steady state (Vd) and the plasma  protein binding 
(ppb) of 70 drugs, belonging to different chemical groups, were collected from the 
literature (Perry 2002; Moffat et al 1986; Lam et al 1997; Durnas et al.1990; Schoerlin 
et al 1990; Fulton & Sorkin 1995; Ritschel & Hammer 1980; Ritschel et al 1995; 
Raaflaub & Speiser-Courvoisier 1974; Glare & Walsh 1991; Thummel & Shen 2001; 
Sonne et al 1988; Greenblatt 1981; Potter & Hollister, 2001). Where several Vd values 
were available for a compound, the mean was used in the analyses. The volume of 
distribution of free drug, Vdu = Vd/(1-ppb), was also used for the development of 
predictive models. The compounds and the pharmacokinetic data are listed in Table 1 
together with the relevant references. 
 
 6 
Physicochemical and structural properties 
A total of 75 structural descriptors for these compounds were obtained from various 
software packages. Table 2 lists the descriptors calculated for the drugs and the software 
used. The COSMIC force field in the NEMESIS software was used for energy 
minimisation prior to molecular mechanical parameter calculations. The software was 
distributed by Oxford Molecular Limited (Oxford, England), although it is no longer 
available. For calculation of molecular orbital parameters, the three-dimensional 
structures of the drugs were imported from NEMESIS and minimised using the MNDO 
Hamiltonian in MOPAC version 7.0 (QCPE, Department of Chemistry, Indiana 
University, 800 East Kirkwood Ave., Bloomington, IN 47405-7102). SMILES strings 
were entered into the MOLCONN-Z software. MOLCONN-Z was used to calculate 
topological descriptors. ACD/Log D Suite release 7.0 was used to calculate, among 
others, log P and log D at pH 1 and 7.4. The fraction of the unionised form of drugs and 
log D at pH 7.4 were also calculated from experimental pKa (pKa(Exp)) taken from the 
references (see Table 3) and log P* values taken from the Biobyte database by 
following the formulae below. Note that as the aim was calculation of the unionised 
fraction of drugs, only the first acidic pKa and the first basic pKa were considered.  
 
For weak bases:  fiB = 100/(1+antilog (7.4 - pKa(Exp))) (3) 
 log D7.4calc=log P* + log (1+antilog (7.4-pKa(Exp))) (4) 
 
For weak acids:  fiA= 100/(1+antilog (pKa(Exp) - 7.4)) (5) 
 log D7.4calc = log P* + log (1+antilog (pKa(Exp)-7.4)) (6) 
fucalc=100-(fiA+fiB)  (7) 
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In equations (3-7), fiB, fiA, fucalc are, respectively, percents of cationic, anionic and 
unionised drug at pH=7.4. 
 
Development of QSARs 
Stepwise regression analysis was used to determine statistically significant relationships 
between structural parameters and the volume of distribution. The statistical analyses 
were performed using the MINITAB (release 13.1) statistical software. In order to avoid 
the risk of chance correlations, loss of interpretability and predictability, the number of 
parameters in the models was kept as low as possible. Accordingly, the stepwise was 
cut short when addition of the third or fourth parameter did not add to the 
interpretability and predictability of the models. QSARs were sought for the whole 
dataset and also for the acidic and basic drugs separately. A compound was allocated to 
the acidic group of drugs if the percent ionised as an acid (anionic percent, fiA), was 
higher than the percent ionised as a base (cationic percent, fiB) at pH 7.4 and was 
allocated to the basic group if fiB was higher than fiA. While deletion of outliers often 
improves the statistics of a QSAR, it was decided to keep all the compounds in the 
study, unless they affected the coefficients of equations significantly. 
In order to test the predictive power of the models, the data sets were divided into the 
two equal groups, a training set and test set. To this end, the data were ranked based on 
the ascending Vd values and every other compound was allocated in the test set and the 
remaining compounds were assigned into the training set. Stepwise regression on the 
training set often led to the models containing parameters other than those involved in 
the models for the whole dataset. Therefore, for simplicity, multiple regression analysis 
was performed on the training set using the parameters obtained from the previous 
stepwise regression analyses and the model obtained was used to calculate the Vd 
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values of the compounds in the test set. Fold error of prediction for the test set was 
calculated according to the following equation. Because of the skewed distribution of 
fold error, the geometric mean was calculated and reported as the mean fold error. 
 ( ).. logloglog predobs VdVdantiFoldError -=  (8) 
The following statistical details of the models were noted: n the number of observations, 
r the correlation coefficient, s the standard deviation, F the Fisher statistic and the p 
value. The figures in parentheses with the regression coefficients were standard errors 
of coefficients. 
 
Results 
 
The apparent volume of distribution (Vd) and the extent of protein binding for the 
compounds used in this study are listed in Table 1 together with the relevant references. 
Data were obtained for a wide range of drug substances. These include central nervous 
system agents and other drugs, such as benzodiazepines, barbiturates, hydantoins, 
succinimides, morphine and related analgesics, tricyclic antidepressants, phenothiazine 
derivatives, butyrophenones, anaesthetics, non-steroidal anti-inflammatory drugs and so 
on. The Vd values cover a range of 0.1 - 41 l/kg. Transformation of the Vd data to a 
logarithmic scale leads to a normal distribution with skewness of 0.005.  
 
QSAR model for Vd 
The stepwise regression analyses for Vd resulted in the following equation: 
log Vd = -0.151(±0.13) +0.364 (±0.038) log P -0.260 (±0.039) log D1 -0.086 (±0.027) µMM
 (9) 
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n = 70    s = 0.390       r = 0.787     F = 35.7     p = 0.000 
Equation (9) indicates that there is a correlation between partition coefficient and Vd, 
but the overall relationship is improved by the introduction of other computed 
parameters. The distribution coefficient at pH=1 (log D1) has a negative effect on Vd. 
The distribution coefficient at this extreme pH value represents a different feature of the 
molecules than hydrophobicity alone. At pH 1, acids are completely in their un-ionised 
form and bases are fully protonated, thus acids will have a log D1 value close to their 
log P whereas for bases, log D1 will be much lower than the true log P. In other words, 
log D1 is higher (and therefore, according to equation 9, Vd is lower) for compounds 
which are less ionised at this acidic pH; these are either acidic drugs or drugs with lower 
basicities. It should be noted that the variables in the equation are not strongly 
correlated with each other, and the highest correlation being between log D1 and log P 
with r = 0.488. Log P, log D1 and µMM used in equation (9), as well as log D7.4, are listed 
in Table 1.  
 
QSAR for Unbound Vd 
A common approach to model the volume of distribution is to correct for plasma protein 
binding and derive QSARs for the unbound (intrinsic) volumes (Ritschel & Hammer 
1980; Blakey et al 1997). The fraction of protein-bound drug in plasma, ppb, was 
collected from the literature (see Table 1). The unbound volume of distribution was 
calculated by dividing Vd by the fraction of non-protein-bound drug in plasma. 
Stepwise regression analysis on the unbound volume of distribution (volume of 
distribution of free drug, Vdu) resulted in equation (10). The ppb values of four drugs in 
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Table 1 were not found in the literature and they were omitted from the regression 
analysis: 
 
log Vdu  = -0.424(±0.139) + 0.396(±0.047) log P + 0.056(±0.016) Carom (10) 
n = 66   r = 0.847    s = 0.437    F = 80.0 
where Carom is the number of aromatic atoms in the molecule.  
The equation shows that the volume of distribution of the free (unbound) drug is related 
to the partition coefficient and the number of aromatic atoms (listed in Table 1) in the 
molecule. 
 
QSARs for acidic drugs 
Based on the fiA and fiB values (Table 3), acidic drugs were identified as described in 
the methods. There were 27 such drugs in this group. The following equations resulted 
from the stepwise regression analysis on log Vd and log Vdu: 
 
log Vd = - 2.56(±0.63) + 0.254 (±0.064) log D7.4 - 4.08 (±1.39) Q- + 0.315 (±0.121) MW/V
 (11) 
n = 27         s = 0.333      r = 0.686       F = 7.0 
 
log Vdu=1.92(±0.88) + 0.393(±0.054) log P + 0.218(±0.050) 3χp - 0.297 (±0.099)S(I) (12) 
n = 25  s = 0.259      r = 0.920     F = 38.6 
Note: there were 2 missing ppb values for acidic drugs. 
In equation (11) and (12), Q- is the lowest atomic charge in the molecule, MW/V is 
molecular weight divided by the volume of molecule (density), 3χp is the third order 
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path molecular connectivity index, and S(I) is the highest electrotopological state index 
in the molecule. 
The importance of lipophilicity in the distribution process is expressed by the presence 
of the distribution coefficient at pH 7.4 in equation (11) and the partition coefficient in 
equation (12). In equation (11) the lowest atomic charge in the molecule has a negative 
sign, which shows that the presence of a heteroatom with higher electronegativity is 
favoured. Bearing in mind the significance of the lipophilicity parameter, this suggests 
that an electronegative heteroatom without a free hydrogen atom (non-hydrogen-bond 
donor) will increase Vd. The third parameter in equation (11) is the density of 
molecules meaning that the presence of heavy atoms (bromine, chlorine, oxygen and 
nitrogen atoms) increases log Vd. 
The second parameter in equation (12) is 3χp, which, in addition to the size of the 
molecule, represents the number of three-bond fragments and adjacency of branch 
points of a ring in the molecule (Hall & Kier 2001). When omitted from the stepwise 
regression analysis, alternatives to this parameter were other connectivity parameters 
(fourth, second, first and zero order) and polarisability, which suggests, in this analysis, 
3χp represents mainly the size of the molecule. The negative coefficient of S(I) shows 
the negative effect of increasing the availability of atomic electron densities. Table 3 
shows the values of Q-, MW/V, 3χp and S(I) for all the drugs. 
 
QSARs for basic drugs 
The following equations were obtained for the basic drugs in the dataset: 
 
log Vd=0.586(±0.116) - 0.325(±0.042) log (fucalc/pKa) + 0.149(±0.044) log D7.4 - 0.078(±0.031) 
µMM (13) 
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n = 43      s = 0.319      r = 0.834     F = 29.6 
where log (fucalc/pKa) is the logarithm of the percent of drug unionised at pH 7.4 divided 
by the pKa of the bases. The inclusion of the distribution coefficient at pH 7.4 and µMM 
in equation (13) is analogous to equations (9) and (11). 
Two new parameters are included in the QSAR for the apparent volume of distribution 
of free drug (note that there are two missing ppb data for basic drugs): 
 
log Vdu = -0.004(±0.38) + 0.270 (±0.061) log P + 0.105 (±0.027) Carom + 0.022 (±0.007) ESP- 
+ 0.121 (±0.076) 3κa (14) 
n = 41   s = 0.433      r = 0.854     F = 24.3 
where ESP- is the lowest (most negative) electrostatic potential on the solvent accessible 
surface of the molecule and 3κa is the third order kappa alpha shape index. 
ESP- may be regarded as a measure of the ability to engage in electrostatic interaction 
with positively charged particles.  The positive coefficient shows the detrimental effect 
of such an ability i.e. the higher negative potential leads to lower log Vdu. The 
molecular shape parameter, 3κa, describes the cyclicity of molecular graphs (Kier 1987), 
implying a higher volume of distribution for molecules with fewer rings. Values of ESP- 
and 3κa for all the drugs are listed in Table 3. 
 
Validation of the QSAR models 
Table 4 shows the equations obtained for the training set based on equations (9-14). The 
Vd values predicted for the test sets using the equations for the training sets (equations 
(15-20)) are tabulated in Table 5 for all drugs, acidic drugs and basic drugs. The 
goodness of prediction has been presented by mean fold error and prediction accuracy, 
 13 
i.e. fraction of compounds predicted to have a Vd value within a 2-fold error from the 
experimental value. 
 
Discussion 
 
The distribution of a compound in the human body is a function of its affinity to various 
tissues. It is related to the extent of binding in tissues vs. the extent of binding in plasma 
(Rowland & Tozer 1995). Plasma protein binding limits the concentration of drug 
available for metabolism and distribution in vivo. A common approach to model the 
volume of distribution is to correct for this factor by dividing the Vd by the fraction 
unbound to plasma protein, and derive QSARs for the unbound (intrinsic) volumes 
(Ritschel & Hammer 1980; Blakey et al 1997). This approach has been criticised by 
Davis et al (2000) on the basis that protein binding itself is related to structural 
parameters such as partition coefficient, which are commonly used in QSAR models. 
Lombardo et al (2002) suggested the fraction unbound in tissues (fut) is a better endpoint 
for QSAR analysis than Vd, and subsequently back calculated the Vd. They employed 
the Oie-Tozer equation (Oie & Tozer 1979) to calculate fut based on a knowledge of 
protein-binding and volume of distribution of drugs, as well as the constant values for 
volumes of plasma, extra cellular fluid and remainder fluid, and the ratio of extra 
vascular to intravascular proteins.  
To investigate the effect of protein binding correction in the present study, the unbound 
volume of distribution, Vdu, has been compared to Vd for the development of QSARs. 
Comparison of equations (10), (12) and (14) with equations (9), (11) and (13) shows 
that QSARs for unbound Vd provide statistically better models with higher r and F 
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values. However, predictive ability, as tested by the mean fold errors for the test sets, 
does not reflect this statistical superiority (Figure 1). This could be due to the fact that 
the parameters in equations (10), (12) and (14) may partly describe the protein binding 
extent, leading to higher error of prediction for Vd. To explore this further, unbound Vd 
may be rewritten as a subtraction of the two terms, a Vd term and a protein binding term 
as follows:  
ppb
Vd
ppb
Vd
-
-=
- 1
1loglog
1
log , (21) 
[FIGURE 1 HERE] 
 
The contribution of each term in equation (21) to the relationship with the unbound Vd 
(equation (10)) was examined by regressing log Vd and log 1/(1-ppb) against the 
structural descriptors in equation (10). The results (equations (22) and (23)) show that 
while log P is a significant descriptor of both Vd and protein binding, Carom is describing 
protein binding only. Note that in equation (22) Carom is not statistically significant (p = 
0.587). 
log Vd =  - 0.402(±0.17) + 0.234(±0.058) log P + 0.010(±0.019) Carom (22) 
n = 66   s = 0.524      r = 0.552   F = 13.8 
 
log 1/(1-ppb) = 0.022(±0.131) + 0.162(±0.044) log P + 0.045(±0.015) Carom  (23) 
n = 66   s = 0.411      r = 0.659     F = 24.2 
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Similar conclusions can be drawn from the corresponding equations obtained for acids 
and bases, where, using the example of the acids, none of the parameters of equation 
(12) were statistically correlated to log Vd (results not presented). 
 
All the QSARs obtained in this study include either a partition, or a distribution, 
coefficient parameter. This is consistent with many previously published reports that 
high lipophilicity is associated with large Vd (Van der Graaf et al 1999; Ritschel & 
Hammer, 1980; Van de Waterbeemed et al 2001). Although the experimental log P and 
log D7.4 parameters had also been used in the stepwise regression analysis, only the 
ACD calculated parameters appeared in the QSARs. There was generally good 
agreement between log P* and the ACD calculated log P (r = 0.881). The correlation 
between ACD calculated log D7.4 and log D7.4calc (calculated from experimental pKa and 
log P*) was not as good (r = 0.709). This is probably due to the deviations of calculated 
pKa as well as log P, from the experimental values. For example, one significant outlier 
from the correlation, glutethimide, is an acid with a pKa(Exp) value of 4.52 and an ACD 
calculated pKa of 11.36. The most important feature of equation (9) is that it shows a 
higher volume of distribution for basic drugs compared with the acids (note the negative 
coefficient of the log D1 parameter). This could be due partly to the high protein binding 
of most acidic drugs. Karalis et al (2002) observed that in a class of compounds with 
higher volume of distribution, the acid/base ratio was lower, whereas protein-binding 
extent was highest in the class with lowest volume of distribution. In equation (11) for 
basic drugs, the inclusion of log(fucalc/pKa) shows that drugs with a higher cationic 
fraction have a higher volume of distribution. In addition, Figure 2 reveals that log fucalc 
increases with increase in log (fucalc/pKa) values, and reaches a maximum where it 
remains almost constant with increasing log (fucalc/pKa) values. The maximum 
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corresponds to compounds with low pKa values, where fucalc does not reflect changes in 
pKa. For example fucalc values remain constant at 100.00 for pKa ranges of 0.5 - 2.4 (see 
Table 3). According to equation (13), the stronger the basicity of a drug, i.e. a lower 
percentage in the unionised form and high pKa values, the higher apparent volume of 
distribution it will maintain; this is not due merely to the higher ionisation but also due 
to the electron directing properties of the rest of the molecule (substituents) on the basic 
nitrogen atom of the molecule. 
[FIGURE 2 HERE] 
 
According to Figure 1, the mean fold errors of prediction from the QSAR for log Vd 
show some decrease when the drugs are separated into acidic and basic groups. The 
similar mean fold errors of prediction could be due to the fact that the number of 
chemicals is lower in the acidic and basic drugs sets. This was explored further by 
splitting the datasets in a 4:1 ratio of training to test sets. Mean fold errors of prediction 
using equations 11-14 (separate equations for acids and bases) were decreased to 1.44, 
1.55, 1.73 and 2.06 respectively. On the other hand, the new splitting process did not 
change the prediction errors of equations 9 and 10 significantly. Therefore, the results 
suggest the use of models 11 and 13 for prediction purposes. This will require a 
knowledge of experimental pKa values as well as the calculated parameters of these 
equations. On the other hand, apparent volume of distribution of all drugs could be 
predicted using equation (9), with lower accuracy, without the need of any experimental 
measurement including pKa and the extent of protein binding. Prediction via equation 
(9) has a mean fold error of 2.03. A similar mean fold error has been reported in a 
previous study, where only basic and neutral drugs were studied and the ratio of the 
number of compounds in the test series to those in the training set was 14:50 (Lombardo 
 17 
et al 2002). In comparison with the error normally associated with the prediction using 
the interspecies scaling, which is reported to be ranging from 1.56 to 2.78 (Obach et al 
1997), our mean fold error is encouraging. To confirm this point further, the mean fold 
error for the Vd predictions of a study based on extrapolation from animals to man 
(Mahmood 1998) was calculated to be 1.82. 
In Table 5 nortriptyline, paroxetine and fluoxetine are drugs with a Vd value higher than 
20 l/kg and are included in the test sets of equations 9, 10, 13 and 14. It is only equation 
13 that provides a reasonably accurate predicted Vd value for these drugs. The extreme 
Vd values of paroxeine and fluoxetine have been highly underestimated by equations 9, 
10 and 14, in addition that of nortriptyline has been overestimated by equation 14. 
Oxyphenbutazone, phenybutazone, valproic acid and acetanilide are the drugs with 
extremely low Vd values (lower than 0.2) that are included in the test sets. Equations 9 
and 11 have highly overestimated all the extremely low Vd values, but this is not the 
case for the corresponding Vdu equations 10 and 12. It could be speculated that the low 
Vd values of these drugs are a result of the high ppb values. 
 
Conclusions 
Statistically significant QSARs were constructed for the volume of distribution of a 
group of drugs as a whole and when separated into acids and bases. Unbound volume of 
distribution was also investigated as a possible QSAR target. Comparing the different 
QSARs, it was concluded that although correction of Vd for protein binding improved 
the statistical fit, it lessened the predictive power of the QSAR. This investigation 
presented a predictive model for the prediction of volume of distribution without a need 
for experimental measurements (equation (9)). Also, a more accurate prediction is 
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possible using equations 11 and 13 for acids and bases, but this will require the 
experimental pKa as well as calculated parameters. The mean fold error associated with 
the prediction using equations 9 is approximately 2, which is within the range of mean 
fold errors of prediction using the extrapolation methods from animal species. The 
advantage of the model is that all the parameters are computed and there is no need for 
experimental measurements. The model could find use in novel drug design and high 
throughput screening laboratories.  
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Table 1 Drugs considered and the apparent volume of distribution (Vd) and protein 
binding (ppb) collected from the literature together with the corresponding partition 
coefficients, distribution coefficients at pH 1 and pH 7.4, dipole moments and the 
number of aromatic carbon atoms. 
Name Vd 
(l/kg) 
Ref. ppb Ref. log P log D1 log D7.4 µMM Carom 
Acetaminophen 1.203 (d, g) *  0.34 0.31 0.34 3.22 6 
Acetanilide 0.161 (b) *  1.08 1.08 1.08 3.88 6 
Alprazolam 0.813 (a, b, k) 0.700 b 2.50 0.99 2.50 6.72 12 
Amitriptyline 10.643 (a, b, g) 0.940 b 4.92 1.82 3.10 0.89 12 
Amobarbital 1.000 (b, g) 0.550 b 2.05 2.05 1.99 0.47 0 
Amphetamine 3.773 (b, b, g) 0.275 b 1.81 -1.29 -0.63 1.40 6 
Bromazepam 1.183 (b, d, i) 0.550 b 2.06 1.01 2.06 4.34 12 
Bupivacaine 1.000 (b) 0.900 b 3.64 0.53 2.80 4.16 6 
Bupropion 13.133 (a, k) 0.850 b 3.47 0.37 3.27 1.33 6 
Butorphanol 5.000 (b) 0.900 b 3.77 0.67 3.10 1.10 6 
Caffeine 0.533 (b, b, g) 0.350 b -0.13 -0.28 -0.13 4.21 0 
Carbamazepine 1.133 (a, b, b) 0.750 b 2.67 2.66 2.67 3.93 12 
Chloral hydrate 0.600 (b) 0.350 b 1.27 1.27 1.27 1.09 0 
Chlordiazepoxide 0.337 (a, b, g) 0.935 b 2.49 1.22 2.49 4.52 12 
Chlorphentermine 2.500 (b) *  2.75 -0.35 0.46 3.00 6 
Clobazam 1.120 (d) 0.850 b 2.34 1.70 2.34 5.15 12 
Clomipramine 14.667 (b, n) 0.925 b 5.53 2.37 3.50 2.39 12 
Clonazepam 3.127 (a, b, g) 0.850 b 2.34 1.70 2.34 3.13 12 
Clorazepate 0.720 (a, b, k) 0.970 b 3.70 1.80 0.08 6.61 12 
Desipramine 33.667 (a, b, n) 0.800 b 4.13 0.62 1.39 1.58 12 
Diazepam 1.920 (a, c, g) 0.985 b 2.96 1.11 2.96 4.00 12 
Doxepine 10.267 (a, a, b) 0.800 b 3.86 0.76 2.07 0.76 12 
Ethclorvynol 2.500 (b) 0.600 b 2.06 2.06 2.06 0.92 0 
Ethosuximide 0.677 (b, g, g) 0.000 b 0.38 0.38 0.38 2.42 0 
Etidocaine 2.000 (b) 0.940 b 3.77 0.66 3.30 4.53 6 
Fentanyl 3.600 (d) 0.800 b 3.89 0.79 2.23 4.04 12 
Flunitrazepam 4.000 (b) 0.780 b 1.25 0.51 1.25 3.00 12 
Fluoxetine 41.000 (a, b, k) 0.940 b 4.09 0.99 1.56 2.75 12 
Gllutethimide 3.077 (b) 0.540 b 2.70 2.70 2.70 3.47 6 
Haloperidol 16.007 (a, b, e) 0.900 b 3.01 -0.09 2.11 3.89 12 
Ibuprofen 0.100 (b) 0.990 b 3.72 3.72 0.80 4.41 6 
Imipramine 17.247 (a, b, e) 0.900 b 4.80 1.29 2.75 1.24 12 
Indomethacin 0.963 (b) 0.950 b 3.10 3.10 -0.01 3.56 12 
Ketamine 4.000 (b) 0.350 b 2.18 -0.92 2.13 3.38 6 
Lidocaine 1.443 (b, c, h) 0.700 b 2.36 -0.75 1.20 4.69 6 
Lorazepam 1.203 (a, b, g) 0.900 b 2.47 2.42 2.47 4.58 12 
Maprotiline 22.000 (a, b) 0.900 b 4.51 1.41 1.65 1.20 12 
Meprobamate 0.700 (b) 0.200 b 0.70 0.70 0.70 0.11 0 
Meptazinol 5.470 (d) 0.270 b 3.70 0.60 1.61 1.35 6 
Methadone 3.940 (b, g, k) 0.900 b 4.20 1.10 2.56 1.82 12 
Methaqualone 6.000 (b) 0.850 b 2.50 0.84 2.50 3.07 12 
Metoclopramide 3.000 (b) 0.650 b 2.22 -0.95 0.05 5.30 6 
Midazolam 1.913 (b, e) 0.950 b 3.93 1.13 3.92 5.46 12 
Moclobemide 1.290 (e) 0.500 e 0.84 -2.26 0.72 3.88 6 
Morphine 3.210 (b, g, h, j) 0.250 b 0.43 -2.67 -0.49 2.23 6 
Naloxone 3.000 (b) 0.400 b 1.45 -1.65 1.36 3.37 6 
Nitrazepam 2.280 (b, d, g) 0.865 b 2.18 0.39 2.18 3.67 12 
Nortriptyline 21.333 (a, b, b) 0.925 b 5.65 2.55 3.11 1.29 12 
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Oxazepam 0.803 (a, g, l, m) 0.950 b 2.31 1.57 2.31 3.38 12 
Oxyphenbutazone 0.107 (b, b, g) 0.990 b 2.72 2.72 1.98 1.50 12 
Paroxetine 25.333 (a, b, n) 0.950 b 3.63 0.53 1.42 2.77 12 
Pethidine(meperidine) 4.953 (d, d, g) 0.450 b 2.35 -0.75 1.15 2.62 6 
Phenacetin 1.310 g 0.300 b 1.63 1.61 1.63 1.91 6 
Phenazone(antipyrine) 0.590 (d, g) 0.100 b 0.27 -0.14 0.27 0.00 6 
Phencyclidin 6.000 (b) 0.725 b 4.88 1.78 3.18 6.08 6 
Phenobarbital 0.827 (c, c, g) 0.500 b 1.67 1.67 1.56 0.40 6 
Phenylbutazone 0.159 (b, g) 0.990 b 3.16 3.16 2.11 1.73 12 
Phenytoin 0.613 (c, g, k) 0.900 b 2.52 2.52 2.48 2.65 6 
Prazepam 1.500 (b) 0.970 b 3.86 1.99 3.86 4.26 12 
Primidone 0.600 (b) 0.200 b 0.40 0.40 0.40 4.47 6 
Propofol 3.500 (f) 0.975 f 4.16 4.16 4.16 1.38 6 
Protriptyline 14.763 (a, b, g) 0.920 b 5.06 1.96 2.21 1.15 12 
Salicylamide 0.147 (b, b, g) 0.750 b 1.41 1.41 1.37 4.31 6 
Serteraline 20.000 (b) 0.980 b 4.81 1.71 2.77 2.34 12 
Temazepam 1.257 (b) 0.970 b 2.20 1.53 2.20 4.57 12 
Theobromine 0.750 (b) *  -0.72 -0.84 -0.72 3.06 0 
Tramadol 3.000 (b) 0.050 b 2.51 -0.59 0.36 2.23 6 
Triazolam 1.113 (a, e) 0.780 b 3.45 1.15 2.62 8.05 12 
Valproic acid 0.173 (a, b, h) 0.900 b 2.72 2.72 0.16 1.65 0 
Viloxazine 1.000 (b) 0.865 b 1.10 -2.00 0.04 0.71 6 
a Perry, P.J (2002); b Moffat et al (1986); c Lam et al (1997); d Durnas et al.(1990); 
e Schoerlin et al (1990); f Fulton & Sorkin (1995); g Ritschel & Hammer (1980); 
hRitschel et al (1995); i Raaflaub & Speiser-Courvoisier (1974); j Glare & Walsh 
(1991); k; Thummel & Shen (2001); l Sonne et al (1988); m Greenblatt (1981); n Potter & 
Hollister (2001). 
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Table 2 The physicochemical and structural descriptors used in the study. 
Method Parameter 
Nemesis  Solvent accessible surface area (SA), dipole moment calculated by the 
Charge-2 method (µMM), the highest and the lowest electrostatic 
potentials on the solvent accessible surface (ESP+ and ESP- respectively) 
MOPAC 7.0 
(MNDO 
Hamiltonian) 
The energies of the highest occupied and the lowest unoccupied 
molecular orbitals (EHOMO and ELUMO, respectively), dipole moment (µ), 
the highest and the lowest atomic charges in the molecule (Q+ and Q-), 
principle moments of inertia (IM), length of the molecule (l), molecular 
weight (MW)  
MOLCONN-Z Simple and valence corrected molecular connectivity indices including 
zero through fourth order path (0χp - 4χp and 0χvp - 4χvp), fourth order path-
cluster (4χpc and 4χvpc), third and fourth order cluster (3χc, 4χc, 3χvc and 
4χvc) and fifth and sixth order chain (5χch and 6χch), the highest atomic 
electrotopological index (S(I)), molecular shape indexes (0κ - 3κ and 0κa - 
3κa), and delta connectivity indexes (X0 - X3) 
ACD/LOGD Calculated partition coefficient (log P), calculated distribution coefficient 
at pH 7.4 and 1 (log D7.4 and log D1), calculated pKa (pKa), the fraction 
unionised at pH 7.4 (fu), polarisability (α), molecular volume (V), molar 
refractivity (MR) and parachor (PA) 
Experimental 
parameters 
Experimental pKa obtained from the literature ((pKa(Exp)), see Table 3 for 
the references); log P obtained from the Biobyte database star list (log 
P*); log D7.4calc is log D calculated using pKa(Exp) and log P values at pH 
7.4; fiB, fiA and fucalc are, respectively,  cationic, anionic and  unionised 
percents at pH=7.4 calculated using pKa(Exp) values   
Other 
parameters 
The total number of oxygen and nitrogen atoms (NN+O), number of 
hydrogen atoms connected to oxygen or nitrogen (NH), number of double 
bonds (N=), number of rotatable bonds (Nrotat), total number of bonds 
(Nbond), number of aromatic carbon atoms (Carom), number of aliphatic 
carbon atoms (Calip), logarithms of molecular surface area and weight 
(log SA and log MW), logarithm of the unionised fraction at pH=7.4 
divided by the experimental pKa (log(fucalc /pKa(Exp))), molecular volume 
divided by the length (V/l) and molecular weight divided by the volume 
(MW/V) 
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Table 3 Experimental pKa values for acids and bases, percent ionised as an acid and as 
a base (fiA and fiB) and percent unionised (fucalc), together with the values of Q-, 
MW/V, 3χp, S(I), ESP- and 3κa  for the drugs in this study. 
Name pKa(Exp)
(acid) 
pKa(Exp) 
(base) 
fiA fiB fucalc Q- MW/
V 
3χp S(I) ESP- 3κa 
Acetaminophen 9.50 b * 0.788 0.000 99.2 -0.38 2.16 2.94 10.52 -35.1 2.49 
Acetanilide * 0.50 b 0E+00 1E-05 100.0 -0.39 1.34 2.53 10.50 -36.2 2.33 
Alprazolam * 2.40 a 0.000 0.001 100.0 -0.25 1.25 8.58 6.26 -58.0 2.29 
Amitriptyline * 9.40 b 0.000 99.010 1.0 -0.41 1.17 7.26 2.42 -26.1 3.09 
Amobarbital 7.94 b * 22.385 0.000 77.6 -0.41 1.26 5.32 11.79 -29.5 2.56 
Amphetamine * 9.94 b 0.000 99.712 0.3 -0.27 0.97 2.53 5.62 -31.1 2.55 
Bromazepam 11.00 a 2.90 a 0.025 0.003 100.0 -0.39 2.13 6.81 11.66 -44.1 2.47 
Bupivacaine * 8.00 a 0.000 79.924 20.1 -0.47 1.18 6.80 12.54 -44.0 3.69 
Bupropion * 7.00 b 0.000 28.475 71.5 -0.36 1.07 4.31 11.92 -34.0 3.73 
Butorphanol * 8.60 b 0.000 94.065 5.9 -0.46 1.18 10.44 11.95 -40.2 2.05 
Caffeine 14 b 0.60 b 3E-05 2E-05 100.0 -0.43 2.24 5.88 11.49 -38.1 1.09 
Carbamazepine 14.07 b -0.46 b 2E-05 0E+00 100.0 -0.41 1.37 6.35 11.68 -49.2 1.60 
Chloral hydrate 10.00 a * 0.251 0.000 99.7 -0.32 2.30 1.73 8.05 -22.3 3.38 
Chlordiazepoxide * 4.80 a 0.000 0.251 99.7 -0.37 1.55 7.57 12.57 -39.6 2.74 
Chlorphentermine * 9.60 b 0.000 99.373 0.6 -0.26 1.46 3.04 5.75 -33.6 3.63 
Clobazam 8.59 * 6.060 0.000 93.9 -0.40 1.18 7.88 12.48 -39.9 2.49 
Clomipramine * 9.46 a 0.000 99.137 0.9 -0.45 1.15 7.61 6.27 -24.9 3.54 
Clonazepam * 1.57 a 0.079 0.000 99.9 -0.38 1.48 7.70 11.67 -32.8 2.52 
Clorazepate 3.50 a * 99.987 0.000 0.0 -0.37 1.76 7.92 11.31 -44.9 2.86 
Desipramine * 10.20 b 0.000 99.842 0.2 -0.37 1.18 7.09 3.24 -28.5 2.79 
Diazepam * 3.30 a 0.000 0.008 100.0 -0.42 1.57 7.98 12.10 -41.6 2.62 
Doxepine * 8.00 b 0.000 79.924 20.1 -0.41 1.19 7.26 5.98 -29.2 3.07 
Ethclorvynol 12.06 * 0.002 0.000 100.0 -0.32 3.43 2.56 9.22 -23.6 2.55 
Ethosuximide 9.30 a * 1.243 0.000 98.8 -0.42 1.16 3.57 10.70 -34.3 1.12 
Etidocaine * 7.70 a 0.000 66.614 33.4 -0.41 1.02 6.42 12.57 -47.6 4.42 
Fentanyl * 8.40 b 0.000 90.909 9.1 -0.47 0.89 8.64 12.52 -42.5 4.77 
Flunitrazepam * 1.80 a 0E+00 3E-04 100.0 -0.42 1.48 8.74 14.14 -38.1 2.67 
Fluoxetine * 10.06 0.000 99.782 0.2 -0.35 1.22 6.65 12.60 -26.9 4.37 
Glutethimide 4.52 b * 99.868 0.000 0.1 -0.42 1.23 5.92 12.03 -34.9 1.82 
Haloperidol * 8.30 b 0.000 88.818 11.2 -0.41 1.45 9.30 13.18 -41.8 4.92 
Ibuprofen 5.20 b * 99.373 0.000 0.6 -0.31 1.06 4.49 10.76 -40.5 3.48 
Imipramine * 9.50 b 0.000 99.212 0.8 -0.45 1.12 7.26 2.52 -26.8 3.12 
Indomethacin 4.50 a * 99.874 0.000 0.1 -0.38 2.10 9.12 12.99 -36.8 3.27 
Ketamine * 7.50 a 0.000 55.731 44.3 -0.37 1.28 6.02 12.18 -43.6 1.91 
Lidocaine * 7.86 b 0.000 74.254 25.7 -0.44 1.06 5.35 11.89 -46.2 3.95 
Lorazepam * 1.3 a 0.008 0.000 100.0 -0.35 1.90 7.71 11.79 -49.5 2.86 
Maprotiline * 10.02 b 0.000 99.761 0.2 -0.35 1.19 8.41 3.31 -28.9 1.80 
Meprobamate 13.39 * 1E-04 0E+00 100.0 -0.41 1.32 3.03 10.37 -38.4 5.49 
Meptazinol * 8.70 a 0.000 95.227 4.8 -0.43 2.31 5.43 9.58 -25.1 2.65 
Methadone * 8.25 b 0.000 87.623 12.4 -0.44 2.16 8.07 13.17 -38.3 3.53 
Methaqualone * 2.54 a 0.000 0.001 100.0 -0.36 1.43 7.25 12.67 -43.7 1.97 
Metoclopramide * 9.00 a 0.000 97.550 2.5 -0.42 1.16 6.58 12.11 -50.5 4.82 
Midazolam * 6.20 a 0.000 5.935 94.1 -0.35 1.53 8.71 14.23 -40.3 2.10 
Moclobemide * 6.89 0.000 23.608 76.4 -0.43 1.35 5.78 11.83 -40.0 4.36 
Morphine 9.26 a 8.18 a 1.362 85.766 12.9 -0.31 1.38 9.70 10.44 -27.9 1.26 
Naloxone * 7.94 b 0.000 77.615 22.4 -0.35 0.80 10.61 12.60 -32.8 1.54 
Nitrazepam 10.80 a 3.2 a 0.040 0.006 100.0 -0.39 1.43 7.54 11.69 -34.9 2.62 
Nortriptyline * 9.73 b 0.000 99.534 0.5 -0.35 1.21 7.09 3.23 -28.8 2.71 
Oxazepam 11.10 a 1.80 a 0.020 0.000 100.0 -0.37 1.64 7.83 11.81 -44.1 2.74 
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Oxyphenbutazone 4.70 b * 99.801 0.000 0.2 -0.28 1.62 9.43 13.04 -33.9 2.41 
Paroxetine * 9.72 0.000 99.524 0.5 -0.03 1.42 8.89 13.56 -22.2 3.52 
Pethidine * 8.70 b 0.000 95.227 4.8 -0.44 1.23 6.33 12.39 -40.0 2.65 
Phenacetin * 2.20 b 0.000 0.001 100.0 -0.39 1.78 3.47 10.68 -34.1 3.36 
Phenazone * 1.40 b 0E+00 1E-04 100.0 -0.31 1.25 5.10 11.60 -21.3 1.51 
Phencyclidin  * 8.50 b 0.000 92.641 7.4 -0.32 1.04 6.39 2.79 -21.9 2.80 
Phenobarbital 7.40 b * 50.000 0.000 50.0 -0.41 1.33 6.33 11.98 -30.4 1.69 
Phenylbutazone 4.50 b * 99.874 0.000 0.1 -0.28 1.34 8.96 13.00 -33.8 2.31 
Phenytoin 8.33 a * 10.514 0.000 89.5 -0.44 1.41 7.11 12.31 -37.5 1.78 
Prazepam * 2.70 a 0.000 0.002 100.0 -0.42 1.19 8.27 12.59 -43.3 3.07 
Primidone 12.26 * 0.001 0.000 100.0 -0.45 2.09 6.09 11.99 -39.8 1.60 
Propofol 11.00 * 0.025 0.000 100.0 -0.26 1.02 4.14 9.93 -25.2 2.10 
Protriptyline * 10.61 0.000 99.938 0.1 -0.35 1.13 6.84 3.28 -29.8 2.34 
Salicylamide 8.20 b * 13.681 0.000 86.3 -0.36 1.63 3.03 10.48 -24.4 1.41 
Serteraline * 9.47 0.000 99.156 0.8 -0.36 1.41 7.67 6.02 -23.5 2.61 
Temazepam * 1.60 a 0E+00 2E-04 100.0 -0.43 1.93 8.49 12.18 -43.6 2.72 
Theobromine 10.05 b * 0.223 0.000 99.8 -0.40 2.69 4.24 11.12 -39.2 0.76 
Tramadol * 8.30 a 0.000 88.818 11.2 -0.44 1.18 6.56 11.21 -27.4 2.93 
Triazolam * 8.19 b 0.000 86.045 14.0 -0.24 1.70 9.05 6.40 -58.4 2.48 
Valproic acid 5.00 b * 99.603 0.000 0.4 -0.37 0.91 2.26 10.48 -32.1 4.16 
Viloxazine * 8.10 a 0.000 83.366 16.6 -0.34 1.20 5.40 5.74 -26.6 3.78 
a Moffat et al (1986); b Foye et al (1995). 
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Table 4 QSARs developed for the validation of the models. 
Eq. No. Equation for traning set n r s F 
15 (model 9) log Vd = - 0.157 + 0.367 log P - 0.240 
logD1 - 0.101 µMM 
35 0.812 0.377 20.0 
16 (model 10) log Vdu = -0.542 + 0.412 log P + 0.063 
Carom 
32 0.881 0.423 50.5 
17 (model 11)  log Vd = - 2.33 + 0.290 logD7.4 - 3.48 Q- + 
0.252 MW/V 
14 0.663 0.396 3.0 
18 (model 12)  LogVdu = 1.63 + 0.565 log P + 0.219 3χp - 
0.307 S(I) 
13 0.935 0.268 20.1 
19 (model 13)  log Vd = 0.522 - 0.373 log(fucalc/pKa)+ 
0.118 logD7.4 - 0.033 µMM 
21 0.849 0.306 14.6 
20 (model 14)  logVdu = 0.698 + 0.347 log P + 0.047 Carom 
+ 0.023 ESP- + 0.022 3κa 
21 0.856 0.430 11.0 
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Table 5 The observed Vd values and the Vd values predicted using the equations for the 
training set together with the corresponding mean fold error and prediction accuracy. 
Name Vdobs. 
(l/kg) 
Vdpred for drugs in the test sets 
Eq. (9) Eq. (10) Eq. (11) Eq. (12) Eq. (13) Eq. (14) 
Acetaminophen 1.20   0.42  *   
Acetanilide 0.16     0.46  * 
Alprazolam 0.81 0.70 5.28      
Amitriptyline 10.64       
Amobarbital 1.00       
Amphetamine 3.77 4.74 2.77   9.47  6.50 
Bromazepam 1.18   1.38 2.25   
Bupivacaine 1.00 4.29  2.17   3.67  2.08 
Bupropion 13.13 7.83 2.77    3.06  4.61  
Butorphanol 5.00       
Caffeine 0.53 0.27 0.16  0.49 0.13    
Carbamazepine 1.13 0.62 5.17      
Chloral hydrate 0.60 0.79 0.62     
Chlordiazepoxide 0.34       
Chlorphentermine 2.50     8.31  * 
Clobazam 1.12   1.11 1.03   
Clomipramine 14.67       
Clonazepam 3.13 0.95  2.27 1.05  1.68   
Clorazepate 0.72   0.26  2.83    
Desipramine 33.67       
Diazepam 1.92     1.53 0.37  
Doxepine 10.27 10.02 12.78   3.90  19.91 
Ethclorvynol 2.50 1.03 0.81  1.77 1.32   
Ethosuximide 0.68   0.35 0.22    
Etidocaine 2.00 4.09 1.47     
Fentanyl 3.60       
Flunitrazepam 4.00 0.75  1.18    0.83  1.67 
Fluoxetine 41.00 6.75  4.77    17.22 8.63  
Glutethimide 3.08       
Haloperidol 16.01       
Ibuprofen 0.10       
Imipramine 17.25 14.81 15.59   16.16 23.92 
Indomethacin 0.96 0.76 1.55 0.32  1.21   
Ketamine 4.00       
Lidocaine 1.44 2.61 1.93     
Lorazepam 1.20 0.51 1.71     
Maprotiline 22.00       
Meprobamate 0.70 0.83 0.45     
Meptazinol 5.47 8.34 16.76    5.81 40.83  
Methadone 3.94       
Methaqualone 6.00       
Metoclopramide 3.00 2.24 1.97     
Midazolam 1.91 2.91 3.41     
Moclobemide 1.29     1.23 1.41 
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Morphine 3.21     2.23 2.47 
Naloxone 3.00 2.70 1.63     
Nitrazepam 2.28       
Nortriptyline 21.33 14.98 26.19   21.79 31.27 
Oxazepam 0.80   1.11 0.52   
Oxyphenbutazone 0.11 1.09  0.22 0.42 0.17   
Paroxetine 25.33 5.87  2.57    12.21 6.12  
Pethidine 4.95 4.18 3.51   4.66 4.78 
Phenacetin 1.31       
Phenazone 0.59     0.73 3.75  
Phencyclidin  6.00 3.93 19.34    5.24 47.02  
Phenobarbital 0.83       
Phenylbutazone 0.16 1.18  0.33 0.40  0.24   
Phenytoin 0.61 0.79 0.75     
Prazepam 1.50     1.78 1.42 
Primidone 0.60   0.75 0.25   
Propofol 3.50 1.71 0.89      
Protriptyline 14.76 13.02 15.96   37.93  19.37 
Salicylamide 0.15       
Serteraline 20.00       
Temazepam 1.26 0.67 0.40      
Theobromine 0.75 0.30  *     
Tramadol 3.00     2.77 18.41  
Triazolam 1.11 1.05 9.53    3.01  3.30  
Valproic acid 0.17 1.05  0.38     
Viloxazine 1.00       
Prediction 
accuracy  
22 of 35 17 of 34 8 of 13 8 of 12 11 of 22 9 of 20 
Mean fold error  2.03 2.29 1.89 1.99 1.84 2.55 
*: ppb value was not available. 
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Figure 1 Mean fold error of prediction for the test set associated with different models; 
error bars show the average deviation. 
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Figure 2 The plot of logfucalc against log(fucalc/pKa) for all drugs considered in the 
analysis. 
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